Early discontinuation of immune checkpoint inhibitors after objective response in real-world melanoma: Clinical and economic impact.
BACKGROUND Immune checkpoint inhibitors (ICIs) have transformed outcomes in advanced melanoma, but optimal treatment duration remains unclear. Most patients are treated until two years, treatment limiting toxicity (TLT), or progression. This study evaluates real-world outcomes after elective discontinuation of ICIs fol...